Fujifilm Corporation has partnered with Dr. Reddy's Laboratories Ltd and Global Response Aid, a global provider of medical supplies and pharmaceuticals, aimed at overseas deployment of a treatment drug for the novel coronavirus infectious disease, or COVID-19. 
On June 30, a Tripartite Licensing Agreement was concluded between FUJIFILM Toyama Chemical Co., Ltd., Dr. Reddy's, and GRA, concerning the development, manufacture and sales of Avigan Tablets (generic name: favipiravir), which is a potential drug for a treatment of COVID-19. 
Under the Agreement, FUJIFILM Toyama Chemical will grant Dr. Reddy's and GRA the exclusive right to develop, manufacture and sell Avigan outside Japan, and, receive a license fee and royalties on sales.
Based on the agreement, FUJIFILM Toyama Chemical will provide Dr. Reddy's and GRA an array of data on Avigan's preclinical and clinical studies that FUJIFILM Toyama Chemical has accumulated thus far. Dr. Reddy's and GRA, for their part, will make use of this data to swiftly implement clinical studies, targeting COVID-19 patients in India, the Middle East, and other regions where infections have been spreading.
In addition, FUJIFILM Toyama Chemical will grant Dr. Reddy's right to use Avigan's patents of formulation and manufacturing method. Dr. Reddy's will herewith establish a setup for manufacturing drugs of the same quality as Avigan, and utilize GRA's global sales network to supply the manufactured drugs swiftly and in a stable manner.
In urgent need of treatment drug while COVID-19 remains a serious concern, the Fujifilm group will accelerate the development and supply for global deployment of Avigan by partnering with Dr. Reddy's and GRA. The Fujifilm Group will contribute to ending the pandemic by delivering a treatment drug as soon as possible to patients suffering from COVID-19.

A Tripartite Licensing Agreement was concluded between Fujifilm Toyama, Dr. Reddy's Laboratories and GRA, concerning the development, manufacture and sales of Favipiravir ( Avigan) tablets used to treat COVID-19 patients